These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

452 related items for PubMed ID: 35933914

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Inflammation-related molecular signatures involved in the anticancer activities of brigatinib as well as the prognosis of EML4-ALK lung adenocarcinoma patient.
    Ge FJ, Dai XY, Qiu Y, Liu XN, Zeng CM, Xu XY, Chen YD, Zhu H, He QJ, Gai RH, Ma SL, Chen XQ, Yang B.
    Acta Pharmacol Sin; 2024 Jun; 45(6):1252-1263. PubMed ID: 38360931
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Coexistence of a novel NBEA-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to alectinib: A case report.
    Liang Q, Xu H, Liu Y, Zhang W, Sun C, Hu M, Zhu Y, Tan S, Xu X, Wang S, Liu L.
    Lung Cancer; 2021 Dec; 162():86-89. PubMed ID: 34763158
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Identification and characterization of ALK kinase splicing isoforms in non-small-cell lung cancer.
    de Figueiredo-Pontes LL, Wong DW, Tin VP, Chung LP, Yasuda H, Yamaguchi N, Nakayama S, Jänne PA, Wong MP, Kobayashi SS, Costa DB.
    J Thorac Oncol; 2014 Feb; 9(2):248-53. PubMed ID: 24419423
    [Abstract] [Full Text] [Related]

  • 10. EML4-ALK biology and drug resistance in non-small cell lung cancer: a new phase of discoveries.
    Elshatlawy M, Sampson J, Clarke K, Bayliss R.
    Mol Oncol; 2023 Jun; 17(6):950-963. PubMed ID: 37149843
    [Abstract] [Full Text] [Related]

  • 11. Transforming tumoroids derived from ALK-positive pulmonary adenocarcinoma to squamous cell carcinoma in vivo.
    Yokota E, Iwai M, Ishida Y, Yukawa T, Matsubara M, Naomoto Y, Fujiwara H, Monobe Y, Haisa M, Takigawa N, Fukazawa T, Yamatsuji T.
    Hum Cell; 2024 Jul; 37(4):1132-1140. PubMed ID: 38829559
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F.
    Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
    [Abstract] [Full Text] [Related]

  • 17. Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy.
    Peters S, Zimmermann S.
    Curr Treat Options Oncol; 2018 May 28; 19(7):37. PubMed ID: 29808239
    [Abstract] [Full Text] [Related]

  • 18. Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting EGFR mutation.
    Miyanaga A, Shimizu K, Noro R, Seike M, Kitamura K, Kosaihira S, Minegishi Y, Shukuya T, Yoshimura A, Kawamoto M, Tsuchiya S, Hagiwara K, Soda M, Takeuchi K, Yamamoto N, Mano H, Ishikawa Y, Gemma A.
    BMC Cancer; 2013 May 29; 13():262. PubMed ID: 23714228
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Establishment of an acquired lorlatinib-resistant cell line of non-small cell lung cancer and its mediated resistance mechanism.
    Xie B, Qiu Y, Zhou J, Du D, Ma H, Ji J, Zhu L, Zhang W.
    Clin Transl Oncol; 2022 Nov 29; 24(11):2231-2240. PubMed ID: 35852680
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.